Synapse - Jan Bewersdorf

Results (103)

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Research Letter

Badar, T.; Nanaa, A.; Atallah, E.; Shallis, R. M.; Guilherme, S. D. C. C.; Goldberg, A. D.; Saliba, A. N.; Patel, A.; Bewersdorf, J. P.; DuVall, A. S.; more...
Blood Cancer Journal (2024)

Fulltext@MSK | Save

Characterization and diagnosis spectrum of patients with cerebrospinal fluid pleocytosis

Journal Article

Dyckhoff-Shen, S.; Bewersdorf, J. P.; Teske, N. C.; Völk, S.; Pfister, H. W.; Koedel, U.; Klein, M.
Infection (2024)

Fulltext@MSK | Save

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents

Journal Article

Bewersdorf, J. P.; Shallis, R. M.; Sharon, E.; Park, S.; Ramaswamy, R.; Roe, C. E.; Irish, J. M.; Caldwell, A.; Wei, W.; Yacoub, A.; more...
Annals of Hematology (2024)

Fulltext@MSK | Save

Impact of type of hypomethylating agent (HMA) used on outcomes of patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) - A large, multicenter, retrospective analysis

Meeting Abstract

Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
Blood (2023)

Fulltext@MSK | Save

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) who underwent allogenic stem cell transplantation (HSCT)

Meeting Abstract

Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
Blood (2023)

Fulltext@MSK | Save

Intensive induction chemotherapy vs hypomethylating agents + venetoclax (HMA/VEN) in NPM1-mutant newly diagnosed acute myeloid leukemia (AML) - A multicenter cohort study

Meeting Abstract

Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y. W.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Lindsley, C.; more...
Blood (2023)

Fulltext@MSK | Save

Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) with missing molecular data

Meeting Abstract

Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
Blood (2023)

Fulltext@MSK | Save

Post allogeneic stem cell transplant outcomes following response to hypomethylating agent therapy in myelodysplastic syndromes are predicted by persistent international prognostic scoring system-molecular risk

Meeting Abstract

Frumm, S. M.; Kim, H. T.; Kelkar, A. H.; Ho, V. T.; Gooptu, M.; Gibson, C. J.; Koreth, J.; Shapiro, R. M.; Romee, R.; Nikiforow, S.; more...
Blood (2023)

Fulltext@MSK | Save

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) who were treated with hypomethylating agents (HMA)